Fiche publication
Date publication
avril 2026
Journal
CNS drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Roos I, Sharmin S, Ozakbas S, Alroughani R, Eichau S, Grand'Maison F, Boz C, Lechner-Scott J, Buzzard K, Prat A, Khoury SJ, Grammond P, van der Walt A, Blanco Y, Foschi M, Soysal A, Barnett M, Prevost J, Terzi M, Gerlach O, Macdonell R, Sa MJ, Spitaleri D, Laureys G, van Pesch V, John N, Cartechini E, Gouider R, Maimone D, Ramo-Tello C, Hodgkinson S, Slee M, McCombe P, Garber J, Sanchez-Menoyo JL, Al-Asmi A, Kermode AG, Lapointe E, Shaygannejad V, Van Wijmeersch B, Willekens B, Castillo-Triviño T, Taylor B, Mathey G, Le Page E, De Seze J, Ruet A, Clavelou P, Berger E, Zephir H, Kwiatkowski A, Pelletier J, Moreau T, Labauge P, Ciron J, Lebrun-Frenay C, Papeix C, Defer G, Laplaud DA, Thouvenot E, Stankoff B, Maillart E, Al-Khedr A, Bourre B, Casez O, Dos Santos A, Camdessanche JP, Hankiewicz K, Wahab A, Cabre P, Heinzlef O, Pottier C, Moulin S, Magy L, Labeyrie C, Doghri I, Vukusic S, Kalincik T,
Lien Pubmed
Résumé
Patients aged ≥ 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score ≥ 3 within the first year are at highest risk of developing aggressive MS (EDSS ≥ 6 within 10 years). Patients without these features are at lowest risk. This study aimed to evaluate whether high-efficacy disease-modifying therapy (HE-DMT) reduced the risk of relapse and disability accumulation in individuals at high risk of aggressive MS, and whether treatment benefit varied by MS severity.
Référence
CNS Drugs. 2026 04 4;:
